TABLE 2.
Absorbed Doses for Anti-GPA33 DOTA-PRIT with [177Lu]Lu-Gemini or [177Lu]Lu-DOTA-Bn in Nude Mice Bearing Subcutaneous SW1222 Xenografts
| [177Lu]Lu-Gemini | [177Lu]Lu-DOTA-Bn | |||
|---|---|---|---|---|
| Tissue | Absorbed dose (cGy/MBq) | TI | Absorbed dose (cGy/MBq) | TI |
| Blood | 3.99 | 114 | 0.50 | 140 |
| SW1222 tumor | 455 | — | 69.79 | — |
| Heart | 2.62 | 174 | 1.45 | 48 |
| Lungs | 5.16 | 88 | 2.55 | 27 |
| Liver | 6.93 | 66 | 2.16 | 32 |
| Spleen | 5.36 | 85 | 1.86 | 38 |
| Stomach | 0.61 | 746 | 0.27 | 258 |
| Small intestine | 1.13 | 403 | 0.73 | 96 |
| Large intestine | 1.44 | 316 | 0.91 | 77 |
| Kidneys | 14.0 | 33 | 3.94 | 18 |
| Muscle | 3.84 | 118 | 0.43 | 162 |
| Bone | 2.09 | 218 | 1.26 | 55 |